Physician profile
Hannah Wallen
NPI 1962015750
$956.82
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $869 · 2022: $88.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $176.73 | 2021 | |
| Collegium Pharmaceutical, INC. | $174.23 | 2021 | |
| Nevro Corp. | $139.63 | 2021 | |
| Biodelivery Sciences International, INC. | $87.71 | 2021 | |
| Boston Scientific Corporation | $75.97 | 2021-2022 | |
| Almatica Pharma LLC | $72.13 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $61.09 | 2021 | |
| Astellas Pharma US INC | $38.11 | 2022 | |
| Si-Bone, INC. | $32.43 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.11 | 2022 | |
| Redhill Biopharma INC. | $23.86 | 2021 | |
| Ibsa Pharma INC. | $22.30 | 2021 | |
| Allergan, INC. | $13.35 | 2021 | |
| Horizon Therapeutics Plc | $13.17 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Wallen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.